2. Academic Validation
  3. Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors

Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors

  • Bioorg Med Chem Lett. 2012 Sep 1;22(17):5681-4. doi: 10.1016/j.bmcl.2012.06.087.
Junji Miyata 1,  Chiyoshi Kasahara,  Toru Asano,  Shinji Ito,  Norio Seki,  Yasuko Kato,  Noriyuki Morikawa,  Kazuyoshi Nozaki,  Kouji Nishimura,  Hisashi Akamatsu,  Yusuke Taguchi,  Tomonori Yamaguchi,  Yoshito Abe,  Mitsuru Ohkubo,  Toshihiro Watanabe,  Mitsuaki Ohta,  Makoto Takeuchi
Affiliations

Affiliation

  • 1 Drug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. [email protected]
PMID: 22853997 DOI: 10.1016/j.bmcl.2012.06.087
Abstract

An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl)pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor. The compound 1 showed high clearance values in microsomes, however. Modification of the pyrrolidino group to a benzylamino group improved human microsomal stability with a slight loss of in vitro activity. Substitution at the ortho position of the benzyl group ameliorated in vitro activity, and further fluorination of the benzyl group improved microsomal stability in rodents. Representative members of this series, compounds 20 and 23, exhibited efficacy in RANKL-induced osteopenic mice when administered orally at 0.3 mg/kg.

Figures